The biotech iQure Pharma Inc. has announced that the analgesic compound iQ-008 demonstrated efficacy in in vivo experiments. In particular, Wilmington, Delaware-based iQure announced that iQ-008 meets Lipinski’s rule of five criteria. Also known as Pfizer’s rule of five, the Rule of 5 (RO5) helps pharmaceutical companies determine whether a compound is druglike. Additionally, iQure…